BNO Holdings

BNO Holdings is a private, clinical-stage biotechnology company headquartered in Oslo, Norway, focused on the development of therapeutic vaccines for a functional cure for HIV. The company’s core technology centers on synthetic peptide vaccines designed to trigger immune responses against highly conserved regions of the HIV virus. Its lead candidate, Vacc-4x, has demonstrated the ability to reduce viral load and improve immune control in Phase 2 clinical trials. BNO Holdings employs a "Shock and Kill" therapeutic approach, frequently investigating its vaccines in combination with latency-reversing agents to target the latent viral reservoir. The company was established to advance the HIV pipeline originally developed by Bionor Pharma ASA.